Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Neoplasms 9Sarcoma 5Recurrence 5Neoplasm Metastasis 5Lymphoma 5Breast Neoplasms 5Endometrial Neoplasms 4Ovarian Neoplasms 3Solid Tumors 2Prostatic Neoplasms 2Multiple Myeloma 2Glioblastoma 2Carcinoma, Non-Small-Cell Lung 2Solid Tumor 1Primary Myelofibrosis 1Osteosarcoma 1Myelodysplastic Syndromes 1Liposarcoma 1Leukemia 1Leiomyosarcoma 1Hematologic Neoplasms 1Gliosarcoma 1Glioma 1Fallopian Tube Neoplasms 1Colorectal Neoplasms 1Central Nervous System Neoplasms 1Bone Neoplasms 1Advanced Cancers 1

Interventions

Ifosfamide 30Methotrexate 27Doxorubicin 25Cyclophosphamide 24Cisplatin 22Filgrastim 18Etoposide 17Gemcitabine 16Leucovorin 14Magnetic Resonance Spectroscopy 11Temozolomide 10cabozantinib 9apatinib 9Specimen Handling 9Carboplatin 9fludarabine 8X-Rays 8Nivolumab 8Neoadjuvant Therapy 8Irinotecan 8Granulocyte Colony-Stimulating Factor 8Docetaxel 8Zoledronic Acid 7Vincristine 7Sirolimus 7Radiotherapy 7Phantoms, Imaging 7Biopsy 7Topotecan 6Mesna 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Osteosarcoma × ridaforolimus × Clear all
NCT00093080 2015-02-13

Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED)

Merck Sharp & Dohme LLC

Phase 2 Completed
216 enrolled
Sarcoma

Leiomyosarcoma, Liposarcoma, Neoplasm Metastasis, Sarcoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡